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ORIGINAL ARTICLE
Diagnosing musculoskeletal tumours
ROBERT J. GRIMER, SIMON R. CARTER, DAVID SPOONER & RODNEY S. SNEATH
The Royal Orthopaedic Hospital Oncology Service, Birmingham, UK
Abstract
In 1993 we became aware of a worrying increase in apparent errors in the histopathological diagnosis of musculoskeletal
tumours in our Unit. As a result all cases seen over the past 8 years were reviewed by an independent panel. Of the 1996
cases reviewed there was an error in 87. In 54 cases (2.7%) this had led to some significant change in the active management
of the patient. The main areas where errors arose were in those very cases where clinical and radiological features were not
helpful in confirming or refuting the diagnosis. The incidence of errors rose with the passage of time, possibly related to a
deterioration in the pathologist’s health. The error rate in diagnosing bone tumours in previously published series ranges
from 9 to 40%. To ensure as accurate a rate of diagnosis as possible multidisciplinary working and regular audit are essential.
Introduction
There is little doubt that diagnosing musculoskeletal
tumours is far from straightforward. Huvos states in
the introduction to his book that ‘diagnosis and treat-
ment of bone tumours is as much an art as a science’,1
whilst Schajowicz pointed out that ‘some lesions still
present serious and in part unresolved problems of
diagnosis even to the experienced pathologist’.2
In recent years there have been a number of articles
and editorials highlighting not only the difficulties of
biopsying  musculoskeletal  tumours  but  also  com-
menting on the error rates in pathological diagnosis
of these tumours.3–8
The overwhelming message from these papers is
the belief that it is necessary for the biopsy to be car-
ried out in the centre where definitive treatment is
going to be provided. The principle reasons for this
belief are that:
1. appropriate pre biopsy staging can be completed;
2. the optimum method and site of biopsy can be
chosen;
3. the biopsy does not compromise subsequent defin-
itive surgical options;
4. there is the lowest rate of complications following
the biopsy;
5. a  pathologist  experienced in diagnosing muscu-
loskeletal tumours can interpret the biopsy.
These guidelines have been available for many years
yet biopsies are still performed suboptimally. Mankin
et al. in their recent review of biopsy problems7 found
that  there had been no significant improvement in
referral patterns or accuracy of diagnosis over a 10-
year period.
The actual accuracy of the histopathological diag-
nosis has also been commented on in most of the
papers mentioned and error rates have varied from 9
to 36%. All of these error rates have either been based
upon  identifiable  errors  which  have  subsequently
become  apparent  or  on  alterations  in  diagnosis at
national or local tumour registries.
We report here the results of an independent audit
of  one  Unit’s  work  to  show  the  errors  that  have
occurred over an 8-year period.
Background
In 1993 it became apparent that there was a worrying
level  of  possible  inaccuracies  in  histopathological
reports relating to  musculoskeletal tumours at  our
Unit.  It  was  decided that  an  independent enquiry
should  be  instituted  and  following  the
recommendations of this enquiry a review of all cases
seen and treated over the previous 8 years was carried
out.  Recognised  experts  in  musculoskeletal
histopathology were invited to review the cases and
this process took almost 2 years. In any case where an
error in diagnosis was identified that case was double
checked  by  another  pathologist.  An  independent
clinical advisory group consisting of an experienced
pathologist, radiologist, surgeon and oncologist also
advised  whether  there  was  any  detriment  to  the90 Grimer et al.
patient  following  from  that  erroneous  diagnosis.
When an error had arisen then the patient or his/her
next  of  kin,  if  the  patient  had  since  died,  were
informed.  All  living  patients  with  the  correct
diagnosis were also informed.
Results
A total of 1996 cases treated over the 8-year period
from  1985  to  1993  at  this  centre  were  reviewed.
During that time the number of new cases of suspected
musculoskeletal tumours treated at the Unit rose from
108 to 341 per year—a 215% rise in work load.
The total number of errors identified was 87 cases,
representing 4.4% of the total. These errors do NOT
include cases where the reviewing pathologist used a
different name to describe what was essentially simi-
lar pathology with no implications on that patient’s
management.  This  would  include  such  circum-
stances as a fibrosarcoma being re-designated as an
MFH (malignant fibrous histiocytoma) or where a
Grade 2 chondrosarcoma was reclassified as a Grade
3 chondrosarcoma. Cases where the altered diagnosis
may  have  had  some clinical  relevance  in terms of
altered management were always submitted for fur-
ther  review  to  the  independent  clinical  advisory
group. This would include such cases as identifica-
tion  of  a  dedifferentiated  chondrosarcoma  in  a
tumour previously labelled as a low-grade chondrosa-
rcoma (the patient might have needed chemother-
apy) or overdiagnosis of malignancy when the patient
might have had unnecessary surgery, chemotherapy
or radiotherapy.
All  87  cases  were  reviewed  by  the  independent
clinical advisory group, who then decided whether
there  had  been  any  prejudicial  effect  upon  that
patient’s treatment as a result of the misdiagnosis.
There were 21 overdiagnoses of malignancy and 36
underdiagnoses of malignancy.
In some cases the patients had the right treatment
despite  the  wrong  diagnosis,  e.g.,  an  expanding
chondroid lesion was  diagnosed histologically as  a
chondroma but on clinical grounds was treated as a
malignant lesion and resected with a wide margin.
Review histology confirmed that the lesion was in fact
a chondrosarcoma and the patient’s treatment would
not have been changed.
It was concluded that, of the 87 cases where there
was a difference of diagnosis, in 33 this error was of
no clinical significance as all aspects of the treatment
and follow-up were identical.
This left 54 cases where there had been a misdiag-
nosis which had resulted in some detriment to the
patient—a  clinically significant error rate  of  2.7%.
The incidence of these errors increased over the 8-
year time span of this review (Fig. 1).
The significance of the errors was broken down
into three categories depending upon the severity of
the effect upon the patient. In those circumstances
where there had been loss of life or limb as a result of
the error in diagnosis this was labelled a ‘Major’ det-
riment. There were five Major errors.
If the patient had undergone inappropriate treat-
ment  with  chemotherapy  or  radiotherapy  or  there
had been a delay in diagnosis affecting the ultimate
prognosis this was labelled an ‘Intermediate’ error.
There were 17 of these.
A ‘Minor’ error was defined as one in which the
error had caused either a delay or an adjustment to
that patients treatment but which had not obviously
affected the prognosis. There were 32 of these. Typ-
ical examples of this were when an initial biopsy had
been reported as ‘non-diagnostic’ and the patient had
undergone a repeat biopsy before the correct diagno-
sis was made. On review the original biopsy was con-
sidered to be diagnostic and hence the patient had
undergone  an  unnecessary  second  biopsy.  Also
included are cases where the patient was underdiag-
nosed and not given chemotherapy but would nor-
mally have done so if the diagnosis had been correct.
An example of this is a girl who had a lump removed
from the surface of her tibia and it was diagnosed as
Fig. 1. Graphic representation of the percentage of errors per year over the 8 years of this review. The percentage errors already ‘known’ 
are shown shaded whilst those errors revealed by this enquiry are clear.Diagnosing musculoskeletal tumours 91
a  chondroma.  Subsequent  review  confirmed  the
diagnosis of periosteal osteosarcoma but the patient
is well and without recurrence 7 years later!
Of the total 54 cases, there were two patients who
may have had unnecessary amputations. Both cases
were patients who had massive tumours of the pelvis
and  both  had  hemipelvectomies.  In  one  case  the
tumour was diagnosed as a chondrosarcoma (Grade
3) and the amputation was done in the hope of offer-
ing a possible cure. The patient died of metastatic
disease some months later. The review diagnosis was
of osteosarcoma. Had this been known the patient
would have been offered chemotherapy but probably
not amputation because of the very poor prognosis
even with chemotherapy.
Three  patients  had  an  unnecessary  resection  of
tumour and insertion of an endoprosthesis as a result
of  misdiagnosis (one patient  had  treatment  for  an
osteosarcoma but review showed the diagnosis to be
an aneurysmal bone cyst; another had resection of a
pelvic tumour thought to be MFH but on resection
was found to be a plasmacytoma; whilst the third had
treatment for a chondrosarcoma subsequently found
to be myositis ossificans).
Seven patients had unnecessary radiotherapy fol-
lowing resection of a soft tissue sarcoma which on
review turned out to be benign conditions (e.g., intra-
muscular myxomas, nodular fasciitis). Seven patients
had one or more cycles of unnecessary chemotherapy
as a result of the misdiagnosis (e.g., a patient with
osteomyelitis diagnosed as Ewing’s sarcoma). In 16
cases, patients had a second biopsy when in retro-
spect it was felt that the initial biopsy was in fact diag-
nostic (e.g., several cases where a small initial needle
biopsy was felt to provide inadequate material for a
firm diagnosis so an open biopsy was performed).
Some  errors  or  misinterpretations  were  more
common than others:
￿ 10 soft tissue tumours were incorrectly labelled as
either benign or malignant;
￿ eight low-grade central osteosarcomas were all ini-
tially misdiagnosed as benign lesions;
￿ eight nerve sheath tumours were incorrectly inter-
preted as being benign/malignant;
￿ eight tumours were  confused between osteosar-
coma and aneurysmal bone cyst (both over and
underdiagnosis);
￿ six  chondroid  lesions  were  incorrectly  graded
(benign/malignant/dedifferentiated);
￿ five  eosinophilic  granulomas  were  labelled  as
infection;
￿ five non-Hodgkin’s lymphomas of bone were mis-
diagnosed  (usually  being  labelled  as  ‘reactive
bone’);
￿ three cases of osteomyelitis were misdiagnosed (as
osteosarcoma or Ewing’s sarcoma).
It is possible to assess the error rate for the main dif-
ferent diagnoses by identifying the total number of
patients  seen  with  that  condition  over  the  8-year
period and identifying the number of errors both over
and under-diagnosing that condition (Table 1).
Of the 87 errors identified in this review, 25 had
been known to us before the review took place. This
usually occurred in cases of underdiagnosis of malig-
nancy when the patient presented back with recur-
rent tumour and further biopsy confirmed the true
nature of the lesion whereupon review of the original
biopsy almost always confirmed that the tumour had
been present all along. In other cases the resection
histology  was  at  variance  with  the  original  biopsy
diagnosis and review of the biopsy again showed the
presence of the correct lesion. The increasing inci-
dence of these ‘known’ errors with time prompted
this review (Fig. 1).
Discussion
This  review  is  the  first  histopathological  peer
reviewed analysis of any one musculoskeletal pathol-
ogist’s work. All 1996 cases have been checked, not
only by the reviewing pathologist, but also in cases of
disagreement by a third independent pathologist. In
all cases where there was no disagreement between
the  original diagnosis and the review diagnosis we
believe it is reasonable to assume that  an  error of
diagnosis is unlikely.
The difficulty of diagnosing these tumours can be
emphasised by one case where a diagnosis of osteosa-
rcoma was confidently made by a local pathologist,
confirmed by a pathologist at a bone tumour registry
and also by our own pathologist. The patient was
reported to have small lung  metastases on CT scan-
ning. The patient was immediately started on chem-
otherapy and subsequently underwent resection of
the primary tumour. Histology of the resected bone
Table 1. Error rates for the most common tumours over the 8-year period
Tumour
No. treated in 
8 years
Total no. of 
errors
No. under-
diagnosed
No. over- 
diagnosed
Total % 
error rate
Osteosarcoma 330 11 8 3 3.3
Low grade osteosarcoma (includes 
parosteal, periosteal and low-grade 
central tumours)
25 8 8 0 32
Chondrosarcoma 112 4 4 0 3.6
Ewing’s sarcoma 142 1 0 1 0.7
Soft tissue sarcoma 300 17 9 8 5.692 Grimer et al.
showed there was no viable tumour visible and the
lung lesions had  completely  resolved. Three years
later this review changed the diagnosis to that of an
aneurysmal bone cyst. This new diagnosis was con-
firmed by the independent review panel and a third
external pathologist and it was felt that the original
lung lesions were normal variants. The original radi-
ological diagnosis of the bone lesion was consistent
with either diagnosis. This case emphasises the diffi-
culty in diagnosing some lesions and begs the ques-
tion of how many opinions should be sought before
commencing  treatment  of  a  presumed  malignant
condition in a young person.
Diagnosing  bone  tumours  is  a  combination  of
pathology, radiology, clinical presentation and expe-
rience. It is worth noting that in many of the errors
highlighted above the radiology of the lesions is non-
specific and encompasses a broad differential diagno-
sis. Soft tissue lesions cannot be reliably diagnosed
radiologically even with CT or MRI, and low-grade
osteosarcomas are well known for their non-specific
appearance.9 It is not possible to grade chondroid
lesions radiologically and infection is often a radio-
logical  differential  diagnosis  particularly  for  round
cell tumours of bone. Hence the incidence of errors is
not  surprisingly highest  in  those  very  areas  where
radiology and clinical features are least helpful.
Mankin et al. have reported on errors in biopsy
diagnosis twice, once in 1982 and again in 1992.3,7
In the original study in 1982, sixteen centres with a
special interest in musculoskeletal oncology reviewed
20 sequential patients who had been found to have a
bone or soft tissue sarcoma. It was estimated that the
biopsy was  incorrect in 82/329  cases and that  the
error rate was 14% if the biopsy was carried out at a
specialist  centre,  but  was  a  staggering  40%  if  the
biopsy was done at a referring centre. The final his-
topathological  diagnosis  was  not  further  peer
reviewed for this study. As a result of errors in diag-
nosis and execution of the biopsy it was estimated
that 4.5% of patients had an unnecessary amputa-
tion.
In 1992 Mankin et al. repeated a similar study.7 On
this occasion 21  institutions supplied data  on 597
malignant tumours. There was an error rate of 17.8%
(106/597) of the biopsy diagnoses when these diag-
noses were compared with the eventual definitive his-
tology.  Again,  the  final  diagnosis  was  not  peer
reviewed. Mankin et al. themselves categorised these
errors as major or minor depending upon their signif-
icance in terms of the patient’s treatment. Eighty-one
of the errors were major (13.5%), in that the error
significantly affected that patient’s treatment. Major
errors arose in 9% of cases seen at the treatment cen-
tres and in 18.4% of patients biopsied at referring
centres. In 28 cases (4.7%) the error resulted in a sig-
nificant alteration in the treatment protocol, in seven
of  which  it  was  believed  that  there  had  been  an
unnecessary amputation. There were 25 minor errors
which were largely alterations of grade or nomencla-
ture but which had little effect on management.
These two papers represent the most direct com-
parison with our experience, but it is interesting that
in  neither  case  was  the  histological  material  peer
reviewed. It is possible to speculate therefore that the
error rate would have been higher if all the material
had been peer reviewed by an external assessor. Fur-
thermore these errors are only reported for patients
who  were eventually  found to  have  a  diagnosis of
malignancy.  No  mention  is  made  of  those  cases
which were initially overreported as being malignant
but which subsequently turned out to be benign. In
our series the rate of overdiagnosis was almost the
same as that of underdiagnosis.
In their 1982 paper Mankin et al. have analysed
their data by diagnosis and it is therefore possible to
compare  the  error  rates  with  those  we  identified
(Table  2).  For  a  better  comparison we  have  only
included in our results those cases which were under-
diagnosed initially, hence these figures differ slightly
to those found in Table 1.
Another method of assessing errors in diagnosis is
to look at error rates in trials of treatment of bone and
soft tissue tumours. Most (but unfortunately by no
means all) national or international studies of bone
and soft tissue tumours insist on central histopathol-
ogy review as a prerequisite for entry into the study.
In the European Osteosarcoma Intergroup Study the
exclusion  rate  due  to  inaccurate  pathology  was
2.2%,10 whilst Presant et al. found that 12 out of 207
(5.8%) cases entered into the South Eastern Oncol-
ogy Group trials for bone or soft tissue tumours were
excluded for inaccurate diagnosis.4 The Swiss bone
tumour  registry  documented  1100  errors  in  3000
cases (36%) and reports that in 106 cases the original
diagnosis of malignant was changed to benign (3.5%)
and in 124 cases from benign to malignant (4.1%).5
Harris et al. reviewed 413 sarcomas diagnosed in
the North West region of the UK between 1982 and
1984, and agreed with the diagnosis of sarcoma in
76% of cases but found a difference of agreement for
subtyping of 47%, with the highest differences being
for  soft  tissue  sarcomas.6  Even  for  bone  tumours
Table 2. Table to show comparative data for underdiagnosed
malignant bone tumours  between non-specialist and specialist
centres in the USA and the present investigation: USA figures
based on those in Mankin et al.3
Diagnosis
Errors at 
referring 
centre (USA) 
(%)
Errors at 
specialist 
centre (USA) 
(%)
Present
 series 
(%)
Osteosarcoma 17 5 2.5
Low-grade 
osteosarcoma
60 50 32
Chondrosarcoma 42 14 3.6
Ewing’s 14 0 0
Overall error rate 30.1 9.1 4.8Diagnosing musculoskeletal tumours 93
there was an error rate of 25% in patients originally
diagnosed as having osteosarcoma and 20% for chon-
drosarcomas.
A retrospective review such as this is always likely
to introduce bias. A reviewer is never under so much
pressure to produce a diagnosis as the original pathol-
ogist who will be aware that a patient is actually wait-
ing for their diagnosis and treatment will be based on
the results of the biopsy. In many cases delay will
already have arisen as a result of a biopsy carried out
elsewhere  and  review  of  the  original  histological
material  is  always  essential  prior  to  commencing
treatment. This in itself causes delays and sometimes
only inappropriate or inadequate specimens will get
sent  for  review  causing  further  delays.  New  tech-
niques will be available  to a reviewer (e.g., mono-
clonal antibodies) which simply were not accessible
to the original pathologist and this too may prejudice
the results of any review procedure.
All musculoskeletal pathologists accept that there
will sometimes be differences between their biopsy
diagnosis  and  the  eventual  diagnosis  based  upon
resection histology.3,7 Of major concern is the finding
in this  series that  the actual error rate was almost
twice that which the treating team had been aware of
based  on  difference  between  biopsy  and  resection
specimens. No previous study looking at error rates
has ever produced data on peer-reviewed histology,
and hence recognised error rates for bone and soft
tissue tumour diagnosis may in fact be serious under-
estimates.
There  are  still  no  clear  guidelines  for  what  an
‘acceptable’ error rate is in histopathology, although
it is generally accepted that an error rate of up to 1%
in general pathology reporting is possible.11,12 The
overall error rate in this study was, in fact, the lowest
ever  reported  for  diagnosing bone  and  soft  tissue
tumours despite the rigorous nature of the review. It
was the deterioration with time that  prompted the
review and which revealed that the actual error rate
was almost twice that which was perceived.
There is little doubt that musculoskeletal histopa-
thology is highly specialised and should not be under-
taken on an occasional basis. A pathologist is just one
of the team making the diagnosis and he/she should
not work in isolation and should have ready access to
second  opinions.  Participation  in  regular  quality
assurance is essential.
For all cancers the problem of underdiagnosis is
one of delay in detection. The tumour will almost
certainly  reveal  itself  eventually  and  the  diagnosis
become apparent. Overdiagnosis of malignancy is the
real problem which may go completely undetected
and indeed be responsible for some ‘miracle cures’.
Entry of patients into cancer treatment trials where
histopathological peer review is  carried out should
detect these.
This enquiry took 2 years to complete, cost over
£100 000 simply for the review process and caused
considerable  distress  and  anguish  to  many  of  the
2000  patients  and  their  relatives  who  had  been
touched by it. The costs of resolving litigation as a
result of the enquiry total over £2 million.
This review has confirmed that  diagnosing bone
and  soft  tissue  tumours is  difficult  and  we  firmly
believe  that  referral  to  a  specialist  centre  prior  to
biopsy should be the aim of all who deal with such
cases.
In order to prevent instances such as this ever hap-
pening again, we would urge that all involved in man-
aging  musculoskeletal  tumours  should  heed  the
lessons  from  this  review  and  in  particular  should
ensure:
1. that multidisciplinary team review of all suspected
musculoskeletal tumour diagnoses is  mandatory
before treatment is commenced;
2. no member of the team, be it surgeon, pathologist,
radiologist or oncologist should ever work in isola-
tion;
3. that regular audit of all aspects of the Unit is man-
datory, ideally involving review with other units.
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